Share

July 24, 2018; 91 (4) Article

Female sex hormones in men with migraine

Willebrordus P.J. van Oosterhout, Guus G. Schoonman, Erik W. van Zwet, Olaf M. Dekkers, Gisela M. Terwindt, Antoinette MaassenVanDenBrink, Michel D. Ferrari
First published June 27, 2018, DOI: https://doi.org/10.1212/WNL.0000000000005855
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
400

Share

Article Information

vol. 91 no. 4 e374-e381
DOI: 
https://doi.org/10.1212/WNL.0000000000005855
PubMed: 
29950439
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received November 24, 2017
  • Accepted in final form April 19, 2018
  • First Published June 27, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Willebrordus P.J. van Oosterhout, MD,
    2. Guus G. Schoonman, MD, PhD,
    3. Erik W. van Zwet, PhD,
    4. Olaf M. Dekkers, MD, PhD,
    5. Gisela M. Terwindt, MD, PhD,
    6. Antoinette MaassenVanDenBrink, PhD and
    7. Michel D. Ferrari, MD, PhD
  1. Willebrordus P.J. van Oosterhout, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Guus G. Schoonman, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Erik W. van Zwet, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Statistica Neerlandica co-editor 2015-2017

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Olaf M. Dekkers, MD, PhD,
    5. Scientific Advisory Boards:

    1. Dutch board of Medical Agency (Non-profit)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editor Plos One

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Gisela M. Terwindt, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Supported by grants of the Netherlands Organisation for Scientific Research (NWO) (GMT Vidi 917-11-319), and FP7-EUROHEADPAIN-no.602633

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Antoinette MaassenVanDenBrink, PhD and
    7. Scientific Advisory Boards:

    1. Amgen/Novartis and Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Amgen/Novartis and Lilly/CoLucid: speaker honoraria

    Editorial Boards:

    1. Member of the editorial board of the Journal of Headache and Pain

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) MAP Pharmaceuticals / Allergan (2) Lilly / CoLucid (3) Amgen / Novartis (4) ATI

    Research Support, Government Entities:

    1. (1) NWO (Netherlands Organisation for Scientific Research), VIDI grant number 917.11.349 (2) ZonMw (Netherlands Organisation for Health Research and Development), grant number 849200007 (3) ZonMw (Netherlands Organisation for Health Research and Development), grant number 849100004

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Dutch Brain Foundation, (2) Netherlands Heart Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Michel D. Ferrari, MD, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Cephalalgia, associate editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Medtronic

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Netherlands Organization for Scientific Research (NWO) (2) European Community (3) ZonMW

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Dutch Heart Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurology (W.P.J.v.O., G.G.S., G.M.T, M.D.F.), Medical Statistics (E.W.v.Z.), and Endocrinology (O.M.D.), Leiden University Medical Center, Rotterdam; Department of Neurology (W.P.J.v.O.), OLVG Hospital, Amsterdam; Department of Neurology (G.G.S.), Elisabeth Tweesteden Hospital, Tilburg; and Department of Internal Medicine (A.M.), Division of Vascular Medicine and Pharmacology, Erasmus Medical Centre, Rotterdam, the Netherlands.
  1. Correspondence
    Dr. van Oosterhout w.p.j.van_oosterhout{at}lumc.nl
View Abstract

Article usage

Article usage: June 2018 to October 2023

AbstractFullPdfSource
Jun 20181389029Highwire
Jul 201816285868Highwire
Aug 201853858739Highwire
Sep 201863217783Highwire
Oct 20183661712Highwire
Nov 2018241237Highwire
Dec 2018237911Highwire
Jan 2019252159Highwire
Feb 2019272128Highwire
Mar 201919053Highwire
Apr 201923663Highwire
May 201967772Highwire
Jun 201956855Highwire
Jul 201911930Highwire
Aug 201912766Highwire
Sep 201913366Highwire
Oct 201918785Highwire
Nov 2019210113Highwire
Dec 201915497Highwire
Jan 2020120187Highwire
Feb 202016157Highwire
Mar 202012510Highwire
Apr 202012221Highwire
May 202021942Highwire
Jun 202010212Highwire
Jul 202011920Highwire
Aug 202014555Highwire
Sep 202011011Highwire
Oct 202010530Highwire
Nov 202012720Highwire
Dec 202012600Highwire
Jan 202114054Highwire
Feb 202114130Highwire
Mar 202117244Highwire
Apr 20219865Highwire
May 202111610Highwire
Jun 20219512Highwire
Jul 202112252Highwire
Aug 202110710Highwire
Sep 202112322Highwire
Oct 202113200Highwire
Nov 202116242Highwire
Dec 202112200Highwire
Jan 202213300Highwire
Feb 202212533Highwire
Mar 202215610Highwire
Apr 202213941Highwire
May 202214763Highwire
Jun 202211321Highwire
Jul 202211665Highwire
Aug 202214042Highwire
Sep 202214753Highwire
Oct 202211826Highwire
Nov 202216126Highwire
Dec 202210310Highwire
Jan 202310711Highwire
Feb 202311411Highwire
Mar 202314000Highwire
Apr 202311011Highwire
May 20238000Highwire
Jun 2023102106Highwire
Jul 202312111Highwire
Aug 20238511Highwire
Sep 202313945Highwire
Oct 202311412Highwire

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles